Arbutus Biopharma (LTS:0SGC) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SGC Arbutus Biopharma Corp LTS:0SGC
53 GF Score
Price $3.32
GF Value $35.59
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma FFO per Share?

FFO per Share only applies to REITs.

LTS:0SGC
53GF Score
Arbutus Biopharma Corp LTS:0SGC
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arbutus Biopharma (LTS:0SGC) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $3.32 is trading 90.7% below its estimated GF Value™ of $35.59.

Key valuation signals for LTS:0SGC:

  • FFO per Share:
  • GF Value™: $35.59 vs. price of $3.32 (90.7% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the LTS:0SGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges ABUS:USAI9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for LTS:0SGC

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price
$35.59
GF Value